Incyte: This Profitable Biotech Trades Like A Melting Iceberg

Incyte Corporation ( INCY ) is a profitable late‑stage biotech firm with ~$20 billion in market cap. As far as I can see, INCY's revenue and earnings base keeps diversifying, and while the market has already repriced the stock price toA seasoned consulting specialist at a leading Central Asian bank. The author behind Novo Capital brings half a decade of experience delivering strategic insight and analysis for the bank's clientele within the private banking branch. Launching the career back in 2020 after gra ...